ESTRO 2025 - Abstract Book

S953

Clinical – Head & neck

ESTRO 2025

986

Digital Poster Pretreatment APOE levels and survival in nasopharyngeal carcinoma: A retrospective analysis. Xianming He 1 , Lei Zeng 2 1 The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. 2 Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China Purpose/Objective: This study represents the inaugural endeavor to explore the prognostic value of pretreatment peripheral serum apolipoprotein E (APOE) in patients with non-metastatic nasopharyngeal carcinoma (NPC). Material/Methods: A retrospective collection of pretreatment indicators was conducted for 352 nasopharyngeal carcinoma patients spanning from 2016 to 2020. Receiver operating characteristic curve analysis, along with univariate and multivariate Cox proportional hazards analyses, was employed to assess the correlation between blood APOE and overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRFS). Results: A higher baseline serum APOE level (>71.5 mg/L) was markedly associated with poorer OS (HR = 2.255, 95% CI: 1.232–4.125, p = 0.008) and remained an independent prognostic factor in multivariate Cox regression analysis. Additionally, body mass index (BMI), body surface area (BSA), Epstein-Barr virus (EBV) DNA load, and high-density lipoprotein cholesterol (HDL-C) were also identified as independent predictors of nasopharyngeal carcinoma prognosis. Conclusion: An elevated pretreatment serum APOE level portends a worse prognosis for nasopharyngeal carcinoma patients and is independent of other known prognostic factors. These findings underscore the value of APOE as a potential biomarker for risk stratification and personalized treatment in nasopharyngeal carcinoma.

Keywords: nasopharyngeal carcinoma, apolipoprotein E.

1011

Digital Poster Base of tongue volume and dose as predictors of late dysphagia in oral cavity cancer patients treated with IMRT: a retrospective analysis. Joseph Azria 1 , Arnaud Beddok 2,3,4 , Esteban Brenet 5,6 , Delphine Antoni 7 , Nathaniel Assouly 8 , Laurence Auzeau 1 , Marine Fontaine 9 , Sofiane Guendouzen 10 , Jean Claude Merol 11 , Yacine Merrouche 12 , Stephane Vignot 12 , Philippe Guilbert 9 , Antonio Da Silva Ribeiro Mota 1 1 Radiation Oncology, Jean Godinot Institute, Reims, France. 2 Radiation Oncology, Institut Godinot, Reims, France. 3 Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, USA. 4 CRESTIC, Université de Reims Champagne Ardenne, Reims, France. 5 Otolaryngology and Head and Neck Surgery Department, Robert Debre Hospital, Reims, France. 6 Medical school, URCA Reims Champagne Ardennes University, Reims, France. 7 Radiation oncology, Institut de Cancerologie de Strasbourg Europe (ICANS), Strasbourg, France. 8 ENT department, Jean Godinot Institute, Reims, France. 9 Radiation oncology, Jean Godinot Institute, Reims, France. 10 Unit of Radiophysics, Jean Godinot Institute, Reims, France. 11 Service de Chrirurgie ORL, Centre Hospitalier Universitaire de Reims, Reims, France. 12 Oncology, Jean Godinot Institute, Reims, France